Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dalpiciclib + letrozole + adebrelimab + goserelin
- Development stage
- Unknown
- Lead developer
- Fudan University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Peptides, Small Molecules
- Administration
- Oral, Intravenous, Intramuscular
01
Overview
CL4 is a combination neoadjuvant therapy regimen being evaluated in the FUTURE-NEO umbrella study (NCT04632992) for patients with HR-positive, HER2-negative breast cancer. The regimen is composed of dalpiciclib (SHR6390), a selective small-molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6); letrozole, an aromatase inhibitor that blocks estrogen synthesis; and adebrelimab (SHR-1316), a humanized monoclonal antibody targeting programmed death-ligand 1 (PD-L1). For premenopausal patients, the regimen also includes goserelin, a gonadotropin-releasing hormone (GnRH) agonist used for ovarian suppression. This multi-modal approach aims to overcome endocrine resistance and enhance anti-tumor efficacy by simultaneously targeting the cell cycle, hormonal signaling, and immune evasion pathways.
- Other names
- SHR6390 + letrozole + adebrelimab + goserelin
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)GnRHR (Gonadotropin-releasing hormone receptor)CDK6 (Cyclin-dependent kinase 6)CYP19A1 (Aromatase)CDK4 (Cyclin-dependent kinase 4)
Beyond the preview
Go deeper on dalpiciclib + letrozole + adebrelimab + goserelin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dalpiciclib + letrozole + adebrelimab + goserelin.